WAT Waters Corporation

Waters CE-Marks In Vitro Diagnostic MassTrak Vitamin D Solution

Waters Corporation (NYSE:WAT) announced today that its fully-validated Waters® MassTrak™ Vitamin D Solution is now CE-marked in accordance with IVD Directive 98/79/EC for the quantitative measurement of 25(OH) D2 and D3 (25-OH-VitD) from human plasma and serum. The IVD LC-MS/MS system solution is a complete solution consisting of reagents and consumables, instrumentation, and software and support services for clinical laboratories routinely measuring vitamin D in patient samples*. The Vitamin D solution is currently only available for sale in Europe.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170104005422/en/

Waters CE-Marks In Vitro Diagnostic MassTrak Vitamin D Solution (Photo: Business Wire)

Waters CE-Marks In Vitro Diagnostic MassTrak Vitamin D Solution (Photo: Business Wire)

“Our MassTrak Vitamin D Solution is the first, CE-marked, single-vendor system to measure both vitamins 25(OH) D2 and D3 independently and accurately from human plasma and serum in a single analysis,” said Jose Castro-Perez, Ph.D., Director of Health Sciences, Global Marketing Operations, Waters Corporation. “It’s the ideal solution for clinical laboratories performing (25-OH-VitD) analysis on a routine basis and which may want to standardize (25-OH-VitD) analysis on a single-vendor platform.”

Vitamin D, the main source of which is from dietary intake, is part of a family of fat-soluble secosteroids and has two major forms - ergocalciferol (plant derived Vitamin D2) and cholecalciferol (animal derived Vitamin D3). Vitamin D is also derived from the conversion of 7-dihydrocholesterol to Vitamin D3 following exposure of skin to sunlight. Increasingly, research is revealing the importance of vitamin D in protecting against a host of health problems. In the absence of vitamin D, bones can become brittle and thin. The research also suggests that vitamin D plays a role in modulating cell growth, the function of neuromuscular and immune systems, and reducing inflammation. It also indicates that those most at risk of a vitamin D deficiency are those who shun the sun, have milk allergies, adhere to a strict vegan diet, or suffer from certain diseases.

Due, in part, to mounting evidence of the importance of vitamin D to human health and to news media coverage, Medicare reimbursement volumes of vitamin D laboratory tests rose 83-fold from 2000 – 20101.

The MassTrak Vitamin D Solution is configured with the Waters ACQUITY UPLC® I-Class/ Xevo® TQD IVD System, the MassTrak Vitamin D Kit and MassLynx® (IVD) Mass Spectrometry Software. The MassTrak Vitamin D Kit provides metrological traceability to the National Institute of Standards and Technology (NIST) Standard Reference Material (SRM) 2972, enabling standardization and lot- to-lot consistency for an easy comparison of results from multiple laboratories. For high-volume vitamin D testing, the system is designed for use with an automated liquid handler and custom pipetting script provided with the kit.

LC-MS/MS in the Clinical Laboratory

In pursuit of better accuracy and precision for clinical laboratory analyses, liquid chromatography tandem mass spectrometry (LC-MS/MS) is rapidly becoming the analytical technique of choice. Waters IVD LC-MS/MS medical devices provide clinical laboratories access to technologies delivering selectivity, sensitivity and versatility – performance characteristics that traditional methods, such as immunoassays, often struggle to meet.

Designed to optimize workflow from pre-analytics to post-analytics, our system portfolio offers a wide variety of options for the routine use of LC-MS/MS in the clinical laboratory.

For more information: www.waters.com/vitamind

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE:WAT) develops and manufactures advanced analytical and material science technologies for laboratory dependent organizations. For more than 50 years, the company has pioneered a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis systems.

*For in vitro diagnostic use. Not available for sale in all countries.

1. Arch Pathol Lab Med. 2014 February ; 138(2): 189–203. doi:10.5858/arpa.2013-0149-OA

Waters, UPLC, ACQUITY, ACQUITY UPLC, Xevo, MassLynx and MassTrak are trademarks of Waters Corporation.

EN
04/01/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Waters Corporation

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

Waters Corp: 1 director

A director at Waters Corp bought 1,000 shares at 332.900USD and the significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch